An experimental vaccine against Alzheimer’s disease has cleared its first
hurdle. Elan Pharmaceuticals of Dublin announced this week that the first 100
patients to receive the vaccine had not suffered any serious side effects. Some
showed an immune response. Codenamed AN-1792, the vaccine is a synthetic version
of the amyloid protein that clogs up the brains of patients. The company now
plans to test the vaccine in the US and Europe.
To continue reading, today with our introductory offers
Advertisement
More from 51¶¯Âþ
Explore the latest news, articles and features
Popular articles
Trending 51¶¯Âþ articles
1
Mathematicians stunned by AI's biggest breakthrough in mathematics yet
2
Photos reveal unexpected details from the world's first atomic test
3
The Selfish Gene at 50: Why Dawkins’s evolution classic still holds up
4
We may finally know why dinosaurs like T. rex evolved tiny arms
5
How I used psychology to come back from the worst year of my life
6
The distant world that is our best hope of finding alien life
7
The ‘doomsday’ glacier’s giant ice shelf is about to break away
8
Epic dreaming is leaving people exhausted and distressed
9
Extreme heat hampers children’s early learning
10
CAR T-cell therapy bolstered by stiffening up cancer cells first
